Central Nervous System

The session will review the current clinical management of the most common malignant and benign adult CNS tumors. This review will be followed by an overview of the current clinical practice in the treatment of brain metastases. We will review the evolving role of stereotactic radiosurgery and whole brain radiotherapy in combination with novel therapeutic agents in the treatment of brain metastases. We will discuss in depth the roles of surgery, radiotherapy and chemotherapy in the management of each of these tumors.

Significant recent progress has been made in the management of CNS tumors, with an emphasis on new molecular prognostic and predictive biomarkers that allow for appropriate treatment selection. Recent updates of the 5th edition WHO Classification of CNS tumors in 2021 include new tumor types that will be summarized. The importance of neuroimaging in helping clinicians improve diagnosis, treatment and response assessment for CNS tumors will be emphasized. This session highlights the need for a multi-disciplinary treatment approach in the management of CNS tumors.

Target Audience

The activity is designed to meet the interests of practicing radiation oncologists, radiation oncology residents, medical and clinical physicists, nurses and all other health professionals involved in the field of radiation oncology.

 

Learning Objectives

Upon completion of this activity, participants should be able to do the following:

  • Discuss the role of each modality including surgery, radiotherapy, and chemotherapy in managing the major malignant and benign adult primary CNS tumors
  • Describe the new updates of the 5th edition of the WHO Classification of Tumors of the CNS 2021.
  • Identify the substantial heterogeneity that exists within these tumor types and understand the prognostic and predictive variables that allow for the selection of the appropriate therapy.
  • Discuss key imaging modalities and features to differentiate recurrent tumor and treatment effect.
Course summary
Available credit: 
  • 1.50 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.50 Certificate of Attendance
    This activity was designated for 1.50 AMA PRA Category 1 Credit™.
Course opens: 
03/28/2022
Course expires: 
03/27/2025
Cost:
$0.00
Rating: 
0

Christina Tsien, MD, is employed by Johns Hopkins University and receives compensation from Varian.

All relevant relationships have been mitigated.

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.

ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.

 

Available Credit

  • 1.50 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.50 Certificate of Attendance
    This activity was designated for 1.50 AMA PRA Category 1 Credit™.